Autolus is at the forefront of a revolution in cancer treatment. Chimeric Antigen Receptor (CAR) T cell therapies have been shown to be effective in some haematological malignancies and may have wide applications as a cancer treatment, with the potential for cure in some patients.

Autolus is a leader in T-cell programming and manufacturing technology. Working in partnership with physicians and other healthcare providers, we extract immune cells from patients, equip them with a receptor that targets the cancer cell and infuse them back into the patient in order to develop therapies which we believe will offer cancer patients substantial benefits over the existing standard of care. Autolus' lead program is AUTO1 (obe-cel) currently in a potential pivotal study for relapsed/refractory adult ALL, with data expected in 2022.